The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.
Johnson & Johnson is feeling the pain from Remicade biosimilars outside the U.S. But it's got a message for worried investors who fear this is just the beginning of a massive downward spiral: Biosimilars are not generics.
It's not a new argument, but it's back on the table again now in a big way. Activist investor Artisan Partners is working to convince other investors to back splitting conglomerate Johnson & Johnson into three separate businesses.
Johnson & Johnson is shelling out more than $120 million to settle thousands of lawsuits from women who claim that the company's vaginal mesh inserts caused them pain and injury, months after other companies facing related suits such as Boston Scientific and C.R. Bard announced similar settlement agreements.
Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause.
Johnson & Johnson executives had only a few words on China in the fourth quarter earnings call and even less on Asia outside of the predictable hit from foreign currency swings, with analyst attention focused on M&A moves.
After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.
Johnson & Johnson's hep C sales have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a strong dollar took a toll on the company's top line, too, dragging sales below analyst estimates.
Johnson & Johnson was hoping to put a marketing case around its Bedtime Products for babies to rest, but a federal judge isn't having it.
Johnson & Johnson's DePuy unit has faced plenty of pushback the past few years over its all-metal hip implants, with patients suing the company for alleged design defects causing pain and injury. Now the company is in the hot seat again, and this time, it's for manufacturing problems in the U.K. linked to the devices.